Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Total Current Liabilities (2023 - 2026)

Beta Bionics' Total Current Liabilities history spans 4 years, with the latest figure at $23.2 million for Q1 2026.

  • On a quarterly basis, Total Current Liabilities rose 40.62% to $23.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $23.2 million, a 40.62% increase, with the full-year FY2025 number at $30.9 million, up 46.23% from a year prior.
  • Total Current Liabilities hit $23.2 million in Q1 2026 for Beta Bionics, down from $30.9 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for BBNX hit a ceiling of $30.9 million in Q4 2025 and a floor of $10.6 million in Q4 2023.
  • Historically, Total Current Liabilities has averaged $21.0 million across 4 years, with a median of $21.1 million in 2024.
  • Biggest five-year swings in Total Current Liabilities: surged 99.42% in 2024 and later surged 40.62% in 2026.
  • Tracing BBNX's Total Current Liabilities over 4 years: stood at $10.6 million in 2023, then surged by 99.42% to $21.1 million in 2024, then skyrocketed by 46.23% to $30.9 million in 2025, then dropped by 25.01% to $23.2 million in 2026.
  • Business Quant data shows Total Current Liabilities for BBNX at $23.2 million in Q1 2026, $30.9 million in Q4 2025, and $25.4 million in Q3 2025.